Drug Trial Radar · NCT07646353
First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jul 27, 2026
Primary completion
Apr 10, 2028
Study completion Apr 10, 2028
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jun 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will assess the safety, tolerability, and pharmacokinetic properties of GSK4425689A monoclonal antibody (mAb) in healthy adults, when administered by either intravenous (IV) or subcutaneous (SC) routes.
Conditions
- Malaria, Falciparum
Interventions
GSK4425689A SCBiological
Participants receive GSK4425689A SC.
GSK4425689A IVBiological
Participants receive GSK4425689A IV.
PlaceboDrug
Participants receive Placebo in the same volume and route as the participants receiving GSK4425689A in the same cohort.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs) overall and by severityTime frame: From Day 1 up to Day 364
- Number of participants with serious adverse events (SAEs) overall and by severityTime frame: From Day -28 [informed consent form (ICF) signing] up to Day 364
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.